Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2026—Michigan Medicine implemented two biomarkers, GFAP and UCH-L1, to evaluate traumatic brain injury in the emergency department, aiming to reduce unnecessary CT scans. A retrospective study showed high sensitivity for the markers, but limitations were identified, such as their ineffectiveness for …
January 2026—Despite significant advancements in algorithm development, implementing AI in clinical practice faces a bottleneck. The challenge lies in operationalizing these algorithms within existing clinical workflows, requiring infrastructure, reimbursement structures, and validation frameworks.
January 2026—Cytokine panels are crucial for managing post-CAR T-cell therapy toxicities like CRS, ICANS, and IEC-HS. These panels help identify specific cytokine elevations, guiding the use of targeted cytokine-blocking agents.
January 2026—The 2025 CAP accreditation checklists include new requirements for humidity, specimen self-collection, body fluid crystal analysis, and pneumatic tube transport of blood specimens.
January 2026—The Association for Diagnostics and Laboratory Medicine released new guidance discouraging clot-based testing in patients receiving direct oral anticoagulants (DOACs).
January 2025—A retired pathologist believes pathologists should be more involved in gross examination of specimens, not just microscopic analysis. A pathologist praises the Canadian series “Coroner” for its realistic portrayal of the forensic pathology world, crediting the involvement of a real forensic pathologist as a consultant.
January 2026—The CAP president emphasizes the importance of inspiring others in the field of pathology. This can be achieved by encouraging new voices to join the field, engaging with medical students, and actively participating in the CAP.
January 2026—Federally qualified health centers (FQHCs) in Illinois demonstrated higher guideline adherence for kidney disease testing compared to non-FQHCs. Patients with low eGFR or diabetes at FQHCs were more likely to receive recommended uACR and dual testing, respectively.
January 2026—Ossifying fibromyxoid tumors with lipomatous and cartilaginous differentiation are rare mesenchymal neoplasms that can be challenging to diagnose. A study identified six cases with these features, expanding the tumor’s known histomorphological spectrum.
January 2025—TITAN, a multimodal whole slide foundation model, outperforms existing slide encoders in various diagnostic and prognostic tasks, including rare disease classification. While promising, TITAN’s limitations, such as partial image representation and domain shift, necessitate further validation and workflow integration before clinical use.
